Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Enterprise Value (2017 - 2026)

Denali Therapeutics has reported Enterprise Value over the past 9 years, most recently at -$867.9 million for Q4 2025.

  • Quarterly Enterprise Value fell 4.27% to -$867.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$867.9 million through Dec 2025, down 4.27% year-over-year, with the annual reading at -$867.9 million for FY2025, 4.27% down from the prior year.
  • Enterprise Value was -$867.9 million for Q4 2025 at Denali Therapeutics, down from -$848.2 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$817.9 million in Q1 2025 and troughed at -$1.4 billion in Q1 2021.
  • The 5-year median for Enterprise Value is -$996.0 million (2022), against an average of -$1.0 billion.
  • The largest YoY upside for Enterprise Value was 41.12% in 2021 against a maximum downside of 140.64% in 2021.
  • A 5-year view of Enterprise Value shows it stood at -$865.4 million in 2021, then plummeted by 54.4% to -$1.3 billion in 2022, then rose by 22.58% to -$1.0 billion in 2023, then increased by 19.54% to -$832.3 million in 2024, then fell by 4.27% to -$867.9 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Enterprise Value are -$867.9 million (Q4 2025), -$848.2 million (Q3 2025), and -$899.0 million (Q2 2025).